What is Cogent Biosciences, Inc.'s convertible debentures?

Cogent Biosciences, Inc. (COGT) reported convertible debentures of $223.17M in Q1 2026.

Cogent Biosciences, Inc. COGT Convertible debentures

Convertible debentures at other companies

DexComDXCM

$0—

DropboxDBX

$690.3M+0.2%

Nutanix, Inc.NTNX

$1.35B+0.4%

Mirum Pharmaceuticals, Inc.MIRM

$310.25M+0.6%

Applied OptoelectronicsAAOI

$129.52M-3.5%

Planet LabsPL

$447.57M—

Other financials

Income statement

See full

Operating income-$103.6M-38.3%

Net income-$97.4M-35.2%

EPS (diluted)-$0.53-1.9%

Balance sheet

See full

Cash & equivalents$241.2M+91.4%

Total debt$15.5M-9.4%

Total equity$607.7M+177%

Total assets$903.0M+218%

Cash flow

See full

Operating cash flow-$86.9M-30.6%

CapEx$449.0K-17.9%

Free cash flow-$87.3M-30.2%

Valuation

See full

Market cap$5.9B+816%

Enterprise value$5.68B+951%

P/S749.8×—

Profitability

See full

Operating margin-1,044.3%—

Net margin-950.4%—

FCF margin-184.7%—

Returns & leverage

See full

Return on equity-85.7%+1.7pp

Debt / equity0×-0.1×

Current ratio15.1×+10.0×

Where this comes from

Reported directly by Cogent Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ConvertibleDebtNoncurrent.

The official record: Cogent Biosciences, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Cogent Biosciences, Inc.'s convertible debentures.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Cogent Biosciences, Inc.'s convertible debentures?: Cogent Biosciences, Inc. (COGT) reported convertible debentures of $223.17M in Q1 2026.